Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
1,145.00
-17.20 (-1.48%)
Mar 28, 2025, 3:30 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 83.59B INR in the quarter ending December 31, 2024, with 15.85% growth. This brings the company's revenue in the last twelve months to 311.31B, up 14.74% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
311.31B
Revenue Growth
+14.74%
P/S Ratio
n/a
Revenue / Employee
11.51M
Employees
27,048
Market Cap
953.17B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Dr. Reddy's Laboratories News
- 3 days ago - Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PRNewsWire
- 4 days ago - Dr Reddy's inks pact with China’s Bio-Thera - The Times of India
- 4 days ago - Dr Reddy's inks South East Asia commercialisation, licence pacts with China's Bio-Thera for Stelara, Simponi biosimilars - The Times of India
- 6 days ago - Nifty 50 top losers today, March 25: IndusInd Bank, Dr. Reddy’s, Adani Enterprises, Coal India and more - Business Upturn
- 7 days ago - Pharma and hospital stocks in focus today: Alembic Pharma, Gland Pharma, Apollo Hospital, Fortis Healthcare, Dr Reddy’s [March 24, 2025] - Business Upturn
- 13 days ago - Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03 - Seeking Alpha
- 13 days ago - Alvotech & Dr. Reddy’s receive FDA acceptance for AVT03, a proposed biosimilar to Prolia & Xgeva - Business Upturn
- 13 days ago - Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Business Wire